Established blockbusters Cosentyx and Entresto, plus new multiple sclerosis drug Kesimpta, pushed Novartis AG sales to a healthy level in the second quarter but the closely watched cholesterol treatment Leqvio has yet to make much of a contribution to the Swiss major’s coffers.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?